CSL Behring is a member of SCDAA’s SCD C.A.R.E.S. Consortium.

“We are honored to support the SCD C.A.R.E.S. Consortium.

Together with the sickle cell community, CSL is committed to reshaping the future of care by:
• Advancing meaningful change
• Developing and delivering innovative options
• Improving lives

For more than a century, we have developed treatments and therapies for people with rare conditions. We are proud to listen, learn and partner with the SCD community.”

Learn more about CSL’s clinical trials, conditions we specialize in and our research and development activities.

Featured Clinical Trials

• A Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
• A Study to Assess the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease During Vaso-Occlusive Crisis

Follow CSL on social media

YouTube

The SCD C.A.R.E.S. Consortium aims to change the perception of clinical trials and increase the participation of sickle cell patients in clinical trials to ultimately provide more therapies to the SCD community. Together, the consortium works together to educate and encourage more trial participation while providing opportunities and better options for the treatment of sickle cell disease.

←Return to the SCD C.A.R.E.S. Hub